|
ИСТИНА |
Войти в систему Регистрация |
ФНКЦ РР |
||
Accounting for EGFR mutations in epidemiological analyses of non-small cell lung cancers: Examples based on the International Lung Cancer Consortium dataстатья
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или Scopus- Авторы: Schmid S., Jiang M., Brown M.C., Fares A., Garcia M., Soriano J., Dong M., Thomas S., Kohno T., Ferro Leal L., Diao N., Xie J., Wang Z., Zaridze D., Holcatova I., Lissowska J., Świątkowska B., Mates D., Savic M., Wenzlaff A.S., Harris C.C., Caporaso N.E., Ma H., Fernandez-Tardon G., Barnett M.J., Goodman G.E., Davies M.P.A, Pérez-Ríos M., Taylor F., Duell E.J., Schoettker B., Brenner H., Andrew A., Cox A., Ruano-Ravina A., Field J.K., Le Marchand L., Wang Y., Chen C., Tardon A., Schabath M.B., Shen H., Landi M.T., Ryan B.M., Schwartz A.G., Qi L., Sakoda L.C., Brennan P., Yang P., Zhang J., Christiani D.C., Reis R.M., Shiraishi K., Hung R.J., Xu W., Liu G.
- Журнал: Cancer Epidemiology Biomarkers and Prevention
- Год издания: 2022
- Издательство: American Association for Cancer Research
- Местоположение издательства: United States
- Аннотация: Somatic EGFR mutations define a subset of non-small cell lung cancers (NSCLC) that have clinical impact on NSCLC risk and outcome. However, EGFR-mutation-status is often missing in epidemiological datasets. We developed and tested pragmatic approaches to account for EGFR-mutation-status based on variables commonly included in epidemiological datasets and evaluated the clinical utility of these approaches.\ Through analysis of the International Lung Cancer Consortium (ILCCO) epidemiological datasets, we developed a regression model for EGFR-status; we then applied a clinical-restriction approach using the optimal cutpoint, and a second epidemiological, multiple imputation approach to ILCCO survival analyses that did and did not account for EGFR-status.\ Of 35,356 ILCCO patients with NSCLC, EGFR-mutation-status was available in 4231 patients. A model regressing known EGFR-mutation-status on clinical and demographic variables achieved a concordance-index of 0.75 (95%CI: 0.74-0.77) in the training and 0.77 (95%CI: 0.74-0.79) in the testing dataset. At an optimal cut-point of probability-score=0.335, sensitivity=69% and specificity=72.5% for determining EGFR-wildtype status. In both restriction-based and imputation-based regression analyses of the individual roles of BMI on overall survival of NSCLC patients, similar results were observed between overall and EGFR-mutation-negative cohort analyses of patients of all ancestries. However, our approach identified some differences: EGFR-mutated Asian patients did not incur a survival benefit from being obese, as observed in EGFR-wildtype Asian patients.\ We introduce a pragmatic method to evaluate the potential impact of EGFR-status on epidemiological analyses of NSCLC.\ The proposed method is generalizable in the common occurrence in which EGFR-status data are missing.
- Добавил в систему: Заридзе Давид Георгиевич